医学
动脉硬化
脉冲波速
内科学
溃疡性结肠炎
炎症性肠病
胃肠病学
亚临床感染
相伴的
内膜中层厚度
疾病
心脏病学
血压
颈动脉
作者
Maria Cappello,Anna Licata,V. Calvaruso,Ivana Bravatà,Alessandra Aiello,Daniele Torres,Vittoriano Della Corte,Antonino Tuttolomondo,Maria Perticone,Giuseppe Licata,Antonio Craxı̀,Calogero Cammà
标识
DOI:10.1016/j.ejim.2016.10.004
摘要
Background & Aims Recent studies documented an increased cardiovascular risk in patients with inflammatory bowel disease (IBD). Our study aimed at investigating the prevalence of intima-media thickness (IMT) of the carotid arteries and the arterial stiffness indices as markers of early atherosclerosis in young IBD patients. Methods We recruited 68 consecutive IBD patients, and 38 matched healthy controls less than 45 years old (median age 31.6 ± 8.1 years). Clinical and demographic features, cardiovascular risk factors, history of cardiovascular events, concomitant therapies were registered on a dedicate database. Carotid IMT was evaluated by using high resolution B-mode ultrasonography. Arterial stiffness was assessed by measurement of carotid-femoral Pulse Wave Velocity (PWV) and Augmentation Index (AIx). Results Total cholesterol (P < 0.013) and LDL-cholesterol (P < 0.019) levels were significantly lower in IBD patients compared to controls. Carotid IMT was higher in IBD than in controls (P< 0.047), but there was no statistically significant difference among Crohn's Disease (CD) and Ulcerative Colitis (UC) patients. Moreover, PWV and AIx were significantly higher in patients as compared to controls (P < 0.006 and P < 0.004 respectively). No medication seemed to affect vascular measurements, though stiffness parameters were significantly higher in patients treated with 5-ASA (11.9 (9.7) vs 18.2 (10.2), P < 0.021), suggesting a lack of efficacy of 5-ASA in protecting IBD patients from early atherogenesis. Conclusions Young IBD patients show an increase in subclinical markers of atherosclerosis. Future studies need to address whether these markers result in an increased risk of cardiovascular events in these patient.
科研通智能强力驱动
Strongly Powered by AbleSci AI